The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying

Journal of Gastroenterology

Volumn 45, Issue 4, 2010, Pages 413-421

  Futagami, Seiji ^a   Iwakiri, Katsuhiko ^a   Shindo, Tomotaka ^a   Kawagoe, Tetsuro ^a   Horie, Akane ^a   Shimpuku, Mayumi ^a   Tanaka, Yuriko ^a   Kawami, Noriyuki ^a   Gudis, Katya ^a   Sakamoto, Choitsu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

5 HT4 receptor agonist; Acylated ghrelin; Gastric emptying; Non erosive reflux disease

Indexed keywords

GHRELIN; MOSAPRIDE CITRATE; OMEPRAZOLE; PEPSINOGEN I; PEPSINOGEN II; PROTON PUMP INHIBITOR;

ACYLATION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS MANOMETRY; ESOPHAGUS MOTILITY; ESOPHAGUS PH; FEMALE; GASTROINTESTINAL ENDOSCOPY; HORMONE BLOOD LEVEL; HUMAN; MALE; NON EROSIVE REFLUX DISEASE; PRIORITY JOURNAL; STOMACH EMPTYING; STOMACH FUNCTION DISORDER; TREATMENT DURATION;

ADULT; ANTI-ULCER AGENTS; BENZAMIDES; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRIC EMPTYING; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; GHRELIN; HUMANS; MALE; MANOMETRY; MIDDLE AGED; MORPHOLINES; OMEPRAZOLE; PROTON PUMP INHIBITORS;

EID: 77952721547     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0173-0     Document Type: Article

References (49)

1. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeiser AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted Country, Minnesota. Gastroenterology. 1997;112:1448-56.
2. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut. 1995;37:457-64.
3. Fass R, Naliboff B, Higa L, Johnson C, Kodner A, Munakata J, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology. 1998;115:1363-73.
4. Kamolz T, Velanovich V. Psychological and emotional aspects of gastroesophageal reflux disease. Dis Esophagus. 2002;15:199-203.
5. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-14.
6. Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux, the sensitive esophagus. Gut. 1997;40:587-90.
7. Tew S, Jamieson GG, Pilowsky I, Myers J. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus. 1997;10:9-15.
8. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974-9.
9. Richter JE, Kovacs TO, Greski-Rose PA, Huang section sign B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 1999; 13:795-804.
10. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Nonerosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537-45.
11. Scheffer RC, Tatum RP, Shi G, Akkermans LM, Joehl RJ, Kahrilas PJ. Reduced tLESR elicitation in response to gastric distension in fundoplication patients. Am J Physiol Gastrointest Liver Physiol. 2003;284:G815-20.
12. Penagini R, Carmagnola S, Cantu P, Allocca M, Bianchi PA. Mechanoreceptors of the proximal stomach: role in triggering transient lower esophageal sphincter relaxation. Gastroenterology. 2004;126:49-56.
13. Zerbib F, Bicheler V, Leray V, Joubert M, Bruley des Varannes S, Galmiche JP. H. pylori and transient lower esophageal sphincter relaxations induced by gastric distension in healthy humans. Am J Physiol Gastrointest Liver Physiol. 2001;281:G350-6.
14. Chen CY, Chao Y, Chang FY, Chien EJ, Lee SD, Doong ML. Intracisternal des-acyl ghrelin inhibits food intake and non-nutrient gastric emptying in conscious rats. Int J Mol Med. 2005;16:695-9.
15. Yamada M, Hongo M, Okuno Y, Nishimura N, Ueno M, Kawakami H, et al. Effect of AS-4370 on gastric motility in patients with diabetic autonomic neuropathy. J Smooth Muscle Res. 1992;28:153-8.
16. Kanaizumi T, Nakano H, Matsui Y, Ishikawa H, Shimizu R, Park S, et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol. 1991;41:335-7.
17. Dickman R, Bautista JM, Wong WM, Bhatt R, Beeler JN, Malagon I, et al. Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease (GERD) groups. Am J Gastroenterol. 2006; 101:2463-9.
18. Svedlund J, Sjodin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129-34.
19. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Sale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7:75-83.
20. 13C breath tests: influence of age, sex and body mass index. J Gastroenterol Hepatol. 2006; 21:1832-8.
21. Shindo T, Futagami S, Hiratsuka T, Horie A, Hamamoto T, Ueki N, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009;79:65-72.
22. Schoeman MN, Holloway RH. Stimulation and characteristics of secondary oesophageal peristalsis in normal subjects. Gut. 1994;35:152-8.
23. Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the in the distal esophagus. Am J Gastroenterol. 1974;62:323-32.
24. Trimble KC, Douglas S, Pryde A, Heading RC. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci. 1995;40:1098-104.
25. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463-8.
26. Sanaka M, Urita Y, Sugimoto M, Yamamoto T, Kuyama Y. Comparison between gastric scintigraphy and the 13C-acetate breath test with Wagner-Nelson analysis in humans. Clin Exp Pharmacol Physiol. 2006;33:1239-43.
27. Asai H, Udaka F, Hirano M, Minami T, Oda M, Kubori T, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord. 2005;11:499-502.
28. Asakawa H, Hayashi I, Fukui T, Tokunaga K. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract. 2003; 61:175-82.
29. Endo J, Nomura M, Morishita S, Uemura N, Inoue S, Kishi S, et al. Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography. J Gastroenterol. 2002;37:888-95.
30. Wei W, Ge ZZ, Lu H, Gao YJ, Hu YB, Xiao SD. Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy. J Gastroenterol Hepatol. 2007;22:1605-8.
31. Talley NJ, Verlinden M, Jones M. Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am J Gastroenterol. 2001;96:1422-8.
32. Scott AM, Kellow JE, Shuter B, Cowan H, Corbett AM, Riley JW, et al. Intragastric distribution and gastric emptying of solids and liquids in functional dyspepsia. Lack of influence of symptom subgroups and H. pylori-associated gastritis. Dig Dis Sci. 1993;38:2247-54.
33. Quigley EM, DiBaise JK. Non-erosive reflux disease: the real problem in gastrooesophageal reflux disease. Dig Liver Dis. 2001;33:523-7.
34. Ruth M, Hamelin B, Rohss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-esophageal reflux disease. Aliment Pharmacol Ther. 1998;12:35-40.
35. Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Characteristics of gastroesophageal reflux in symptomatic patients with and without excessive esophageal acid exposure. Am J Gastroenterol. 2006;101:2470-5.
36. Weusten BL, Akkermans LM, vanBerge-Henegouwen GP, Smout AJ. Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. Gastroenterology. 1995;108:1739-44.
37. Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther. 2000;14:389-96.
38. Cicala M, Emerenziani S, Caviglia R, Guarino MPL, Vavassori P, Ribolsi M, et al. Intra-oseophageal distribution and perception of acid reflux in patients with non-erosive gastro-oseophageal reflux disease. Aliment Pharmacol Ther. 2003;18:605-13.
39. Miwa H, Minoo T, Hojo M, Yaginuma R, Nagahara A, Kawabe M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther. 2004;20(suppl 1):112-7.
40. 3 receptor in conscious rats (abstr). Gastroenterology. 2006;130:A-246.
41. Iwakiri K, Kawami N, Sano H, Tanaka Y, Umezawa M, Kotoyori M, et al. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring. J Gastroenterol. 2009;44: 708-12.
42. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006; 55:1398-402.
43. Holloway RH. Esophageal body motor response to reflux events: secondary peristalsis. Am J Med. 2000;108:20-6.
44. Iwakiri K, Hayashi Y, Kotoyori M, Tanaka Y, Kawami N, Sano H, et al. Defective triggering of secondary peristalsis in patients with non-erosive reflux disease. J Gastroenterol Hepatol. 2007; 22:2208-11.
45. Ruth M, Finizia C, Cange L, Lundell L. The effect of mosapride on esophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2003;15:1115-21.
46. Quigley EM. Gastric motor and sensory function, and motor disorders of the stomach. In: Feldman M, Friedman LS, Sleisenger MH, editors. Gastrointestinal and liver disease, pathophysiology/diagnosis/management. Philadelphia: WB Saunders; 2002. p. 691-714.
47. Broglio F, Gottero C, Van Koetsveld P, Prodam F, Destefanis S, Benso A, et al. Acetylcholine regulates ghrelin secretion in humans. J Clin Endocrinol Metab. 2004;89:2429-33.
48. Osawa H, Nakazato M, Date Y, Kita H, Ohnishi H, Ueno H, et al. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab. 2005; 90:10-6.
49. Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, et al. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio-a possible novel and non-invasive marker for gastric atrophy. Hepatogastroenterology. 2004;51:1249-54.